image credit- shutterstock
Onward Therapeutics has announced the completion of a share exchange, under which Onward Therapeutics, Inc. (Onward Taiwan) has become the group's global holding and headquarters, while Onward Therapeutics SA (Onward Switzerland) has become a wholly owned subsidiary of Onward Taiwan.
The group reorganisation involved the exchange of all shares in the former Swiss parent company for shares in the new Taiwan entity, maintaining ownership ratios and board composition.
This milestone marks a strategic step in aligning Onward's global operations and expanding its presence across Asia and Europe. The Taiwan entity brings together Onward's scientific and corporate teams across Taiwan, Switzerland, and France under a unified corporate structure.
Over the past six years, Onward has built a robust pipeline of four innovative programs targeting both solid and hematologic tumours, through in-licensing, acquisition, and internal discovery. The group reorganisation was designed to align Onward's corporate structure with Taiwan's dynamic biotechnology capital market and to support the company's long-term growth plans, including future fundraising and potential public listing.
Building on its strong base of Taiwanese and multinational shareholders, Onward aims to leverage Taiwan's scientific excellence, robust clinical trial infrastructure, and proven capabilities in advanced biopharmaceutical manufacturing to accelerate global development programmes and partnerships. Taiwan's supportive regulatory framework and innovation-driven investment environment further reinforce Onward's ability to pursue sustainable growth and its role as an international enterprise.
